Modern approaches in treatment of diabetes mellitus type 2: glucagon-like peptide-1 receptor agonist and basal insulin combination

• Alexander S. Ametov

AbstractDiabetes mellitus type 2 is extremely widespread chronic disease characterized by progressive course and led to patients’ disability. Obesity, associated insulin resistance and the depletion of pancreatic β-cells functional activity play an important role in pathogenesis of diabetes mellitus type 2. In recent years there was presented a new group of preparations with a good profile of efficiency and safety, which action is based on the incretin effect. The glucagon-like peptide-1 (GLP-1) receptor agonist therapy leads to weight reduction and improvement of a carbohydrate metabolism indicators without significant increase of hypoglycemic states development risk. Combination «exenatide + prolonged insulin» is the high-perspective treatment modality which has some advantages for difficult category of patients with diabetes mellitus type 2 (the obesity patients demanding purpose of an insulin therapy for achievement of compensation of a carbohydrate exchange).

Keywords:diabetes mellitus type 2, incretin, exenatide, prolonged insulin, combine antihyperglycemic therapy, new combinations of blood glucose lowering drugs

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)